PMS2P5

Across TCGA pan-cancer cohorts, PMS2P5 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PMS2P5 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PMS2P5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PMS2P5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where PMS2P5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.283	0.618	<.001	41	view →
LSCC	OS	Median	All	0.915	1.000	.008	19	view →
CCRCC	OS	Tertile	All	1.000	0.353	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PMS2P5–PDAC (DFS)

Open the PDAC breakdown →